Genzyme Transgenics to re-acquire rhATIII rights

GZTC signed a letter of intent to re-acquire rights in Europe and the Americas from parent company Genzyme Corp. ( Cambridge, Mass.) for recombinant human antithrombin III (rhATIII). The rights are al...